PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 67 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $100 | -100.0% | 9,199 | -93.3% | 0.00% | -100.0% |
| Q3 2022 | $1,155,000 | +273.8% | 137,200 | +793.9% | 0.01% | +500.0% |
| Q4 2020 | $309,000 | -83.6% | 15,349 | -90.2% | 0.00% | -87.5% |
| Q3 2019 | $1,885,000 | -38.3% | 156,961 | -35.4% | 0.01% | -38.5% |
| Q1 2019 | $3,053,000 | +77.0% | 242,862 | -5.2% | 0.01% | +44.4% |
| Q4 2018 | $1,725,000 | -32.9% | 256,220 | +2.6% | 0.01% | -18.2% |
| Q3 2018 | $2,570,000 | +63.5% | 249,704 | +6.8% | 0.01% | +57.1% |
| Q2 2018 | $1,572,000 | +215.7% | 233,830 | +303.3% | 0.01% | +250.0% |
| Q1 2018 | $498,000 | +152.8% | 57,981 | +513.0% | 0.00% | +100.0% |
| Q4 2017 | $197,000 | – | 9,459 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |